Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$31.51 -1.6%	$24.27	$16.50 ▼ $32.15	$2.74B	N/A	55,358 shs	2,838 shs
ABUS Arbutus Biopharma	$3.53 -1.4%	$3.30	$2.71 ▼ $4.73	$676.09M	1.23	968,171 shs	507,721 shs
APLS Apellis Pharmaceuticals	$18.83 -2.2%	$18.31	$16.10 ▼ $43.15	$2.37B	0.68	2.34 million shs	1.17 million shs
OGN Organon & Co.	$10.03 -0.4%	$10.08	$8.01 ▼ $23.10	$2.61B	0.58	3.43 million shs	3.34 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	+11.03%	+39.67%	+65.84%	+3,150,999,900.00%
ABUS Arbutus Biopharma	0.00%	+1.44%	+13.14%	+6.97%	+8.62%
APLS Apellis Pharmaceuticals	0.00%	-2.33%	+15.10%	-23.64%	-55.69%
OGN Organon & Co.	0.00%	+4.86%	+13.79%	-34.63%	-51.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ABUS Arbutus Biopharma	2.2206 of 5 stars	3.5	0.0	0.0	0.0	3.2	2.5	0.6
APLS Apellis Pharmaceuticals	4.7585 of 5 stars	4.3	3.0	0.0	4.4	4.1	2.5	0.6
OGN Organon & Co.	4.7788 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ABUS Arbutus Biopharma	3.00	Buy	$5.50	55.81% Upside
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	112.71% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	79.55% Upside

Current Analyst Ratings Breakdown

Latest ABUS, AAPG, OGN, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00
5/8/2025	APLS Apellis Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$28.00 ➝ $20.00
5/8/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $26.00
5/8/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$55.00 ➝ $47.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	2.80	N/A	N/A	N/A	∞
ABUS Arbutus Biopharma	$6.40M	105.59	N/A	N/A	$0.63 per share	5.60
APLS Apellis Pharmaceuticals	$775.84M	3.05	N/A	N/A	$1.64 per share	11.48
OGN Organon & Co.	$6.29B	0.41	$3.21 per share	3.12	($0.27) per share	-37.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ABUS Arbutus Biopharma	-$72.85M	-$0.41	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	7/30/2025 (Estimated)
APLS Apellis Pharmaceuticals	-$528.63M	-$1.79	N/A	N/A	N/A	-34.97%	-103.11%	-28.96%	7/30/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.01	2.68	0.90	13.49%	431.62%	8.03%	8/5/2025 (Estimated)

Latest ABUS, AAPG, OGN, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.80%	N/A	2.78%	N/A

Latest ABUS, AAPG, OGN, and APLS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
ABUS Arbutus Biopharma	N/A	7.02	7.02
APLS Apellis Pharmaceuticals	1.91	4.36	3.73
OGN Organon & Co.	17.73	1.70	1.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ABUS Arbutus Biopharma	43.79%
APLS Apellis Pharmaceuticals	96.29%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ABUS Arbutus Biopharma	20.30%
APLS Apellis Pharmaceuticals	6.50%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.11 million	N/A	N/A
ABUS Arbutus Biopharma	90	191.53 million	181.91 million	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	115.93 million	Optionable
OGN Organon & Co.	10,000	259.96 million	253.93 million	Not Optionable

ABUS, AAPG, OGN, and APLS Headlines

Recent News About These Companies

Securities Class Action Lawsuit Filed Against Organon & Co. (OGN) - Levi & Korsinsky Represents Shareholders

June 15 at 3:45 PM | accessnewswire.com

July 22, 2025 Deadline: Join Class Action Lawsuit Against Organon & Co. (OGN) - Contact Levi & Korsinsky

June 15 at 11:25 AM | accessnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of ...

June 15 at 11:16 AM | gurufocus.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

June 15 at 10:05 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN

June 15 at 10:00 AM | globenewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Organon & Co. ...

June 15 at 9:37 AM | gurufocus.com

Class Action Alert: Levi & Korsinsky Reminds Organon (OGN) Investors of July 22, 2025 Deadline

June 15 at 9:05 AM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

June 15 at 8:48 AM | globenewswire.com

Lost Money on Organon & Co. (OGN)? Join Class Action Before July 22, 2025 - Contact Levi & Korsinsky

June 15 at 8:10 AM | accessnewswire.com

OGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit!

June 15 at 7:00 AM | accessnewswire.com

Securities Lawsuit Alert: Organon & Co. (OGN) Investors - Contact Levi & Korsinsky Before July 22, 2025

June 15 at 6:45 AM | accessnewswire.com

OGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Organon & Co. - July 22, 2025 Deadline

June 14 at 6:10 PM | accessnewswire.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN

June 14 at 2:08 PM | markets.businessinsider.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN

June 14 at 12:00 PM | accessnewswire.com

OGN SHAREHOLDERS: Organon & Co. Investors are Reminded of the Pending Securities Fraud Class Action â€“ Contact BFA Law by July 22 Deadline (NYSE:OGN)

June 14 at 8:00 AM | globenewswire.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 13 at 10:23 PM | prnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN

June 13 at 4:00 PM | accessnewswire.com

Levi & Korsinsky Notifies Organon & Co. (OGN) Shareholders of Class Action Lawsuit and July 22, 2025 Deadline

June 13 at 4:00 PM | accessnewswire.com

OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 13 at 4:00 PM | globenewswire.com

OGN CLASS ACTION NOTICE: Organon & Co. was Sued for Securities Fraud; Contact BFA Law if You Suffered Losses

June 13 at 3:18 PM | accessnewswire.com

Wedmont Private Capital Sells 54,982 Shares of Organon & Co. (NYSE:OGN)

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, AAPG, OGN, and APLS Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$31.51 -0.51 (-1.59%)

As of 06/13/2025 03:28 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Arbutus Biopharma NASDAQ:ABUS

$3.53 -0.05 (-1.40%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.60 +0.08 (+2.12%)

As of 06/13/2025 05:55 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Apellis Pharmaceuticals NASDAQ:APLS

$18.83 -0.43 (-2.23%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$19.15 +0.32 (+1.70%)

As of 06/13/2025 07:39 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Organon & Co. NYSE:OGN

$10.02 -0.05 (-0.45%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$10.01 -0.02 (-0.15%)

As of 06/13/2025 07:13 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time